

October 31, 2016



## **Actinium Pharmaceuticals Announces Key Hire in Clinical Supply Chain Organization as Company Expands To Accommodate Continued Growth**

*- Incoming Industry Veteran to Lead Clinical Supply Chain Operations and Architect the Build Out of the Anticipated Commercial Supply Chain*

NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Bernie Cunningham, Ph.D, to the position of Executive Director of Clinical Supply Chain and Logistics, and CMC Project Management. This new hire will report to Kaushik J. Dave, Ph.D, Actinium's Chief Executive Officer, as a keystone hire in the Company's growing Supply Chain Team.

"We are enormously gratified to welcome Dr. Cunningham to the Actinium Pharmaceuticals team," said Kaushik J. Dave, Ph.D, Actinium's Chief Executive Officer. "The hiring of such a skilled and experienced executive shortly after onboarding Dr. Maria Nunes and Ms. Laura Chen reinforces my confidence in our ability to attract requisite talent as we continue to perfect pre-commercialization capabilities for our phase 2 and phase 3 programs, increase readiness for commercialization and also prepare for pipeline expansion."

Dr. Cunningham will have a leadership role, responsible for further establishment of the Company's supply chain infrastructure and related distribution strategies, all of which will provide critical support to clinical operations both in the United States and outside the United States. She will also oversee Actinium's relationships with external contract manufacturing organizations and contract testing labs for all clinical trial material supplies. Dr. Cunningham has approximately thirty years of experience in the pharmaceutical and biotechnology industries, with a dedication to supply chain and project management within the last fifteen years. As a Certified Project Management Professional she brings extensive experience in development of investigational medical products in various physical forms. She led teams and directed multiple projects in manufacturing, supply chain and QA/QC at companies including Mesoblast and OSI Pharmaceuticals. She began her professional career as a Research Scientist and Principal Investigator at OSI Pharmaceuticals, and most recently had the title of Director, Project Management – Manufacturing and QA at Mesoblast. Dr. Cunningham holds a Ph.D. in Medicinal Chemistry from University of Aston in Birmingham, U.K., as well as a BSc (Hons) from University of Aston, and has written a number of papers published in peer-reviewed pharmacology journals.

## About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate lomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of lomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

## Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin  
Vice President, Finance and Corporate Development  
Actinium Pharmaceuticals, Inc.  
[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)



Source: Actinium Pharmaceuticals